BioAge Labs Investors are Notified to Contact BFA Law About Its Investigation into the Company’s 76% Stock Dro By Investing.com

New York, NY–(Newsfile Corp. – January 4, 2025) – A leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA ) for possible violations of federal securities laws.

If you have invested in BioAge, you are encouraged to learn more by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

Why is BioAge being investigated?

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases with a primary focus on obesity. The company’s lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor ( APJ), designed to promote weight loss.

At the same time, the company said azelaprag was well-tolerated in eight Phase 1 clinical trials in 265 subjects and that following the company’s IPO, it is “well-equipped to advance our clinical programs.[.]”

Stocks are falling as the truth is revealed

On December 6, 2024, BioAge announced that it had stopped the STRIDES Phase 2 trial of azelaprag, citing safety concerns, after liver transaminitis was observed in azelaprag recipients. The decision to stop the Phase 3 study was “made clear” due to “the safety of the current doses tested with the emerging profile.”[.]”

The news caused the company’s stock price to drop more than 76% from a closing price of $20.09 per share on December 6, 2024 to a closing price of $4.65 per share on December 9, 2024.

For more information click here: https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

What can you do?

If you have invested in BioAge, you may have legal options and are encouraged to submit your information to the company.

All representation is on a contingency fee basis, at no cost to you. Shareholders are not responsible for any court costs or litigation expenses. The Company will seek court approval for any fees and costs.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/bioage-labs-inc

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. of Plaintiffs’ Lawyers, and SuperLawyers by Thompson Reuters.From its recent remarkable successes, BFA has recovered more than $900 million from the board of directors of Tesla (NASDAQ: ), Inc. (pending court approval), as well as $420 million from Teva Pharmaceutical (NYSE: ) Ind. Ltd.

For more information about BFA and its attorneys, visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/bioage-labs-inc

Advertisement of a lawyer. Past results do not guarantee future results.

To view the original version of this press release, visit https://www.newsfilecorp.com/release/235856